PHARMA CHINA ANNUAL FORUM[™]

March 30, 2012
Rendezvous Merry Hotel Shanghai, China

Confronting Healthcare Challenges in China

Pharma China Annual Forum

March 30, 2012 - Shanghai

Organizer

Pharma China

Sponsors

RDPAC, others TBA

Supporting Parnter

PharmaGuys

Time

9:00 PM to 5:15 PM, March 30, 2012

Venue

Rendezvous Merry Hotel Shanghai (上海美丽园龙都大酒店), China

396 Yanan Rd. West,Shanghai, China 中国上海市延安西路 396 号

Tel: +86 21 6249 5588

Language

English / limited Mandarin Chinese

Fees

- RMB 4,200 Pharma China subscribers
- RMB 5.500 Non-subscribers

Fees covers attendance, refreshments, lunch, copy of presentations, latest issue of *Pharma China journal edition*

Registration/Enquiries

Space is limited to 80 participants and priorities are given to *Pharma China* subscribers.

Please contact:

David Xue or Jenny Wang Pharma China

Tel: +86 10 8530-0937 or 84476010

Cell: +86 18601267831

Fax: +86 10 5885 7333 ext 0260 E-mail: dxue@pharmaguys.com *and* jenny.wang@pharmachinaonline.com

www.pharmachinaonline.com

Event Introduction

- * Contemporary trends & issues in Chinese Pharma in 2011 and early 2012
- * Healthcare reform and policy impacts on the Chinese pharma sector
- * Pharma-related regulatory developments and market outlook
- * Changing dynamics in Chinese pharma/healthcare landscape
- * Interactive discussion and brainstorming with our panel of top experts

Although there are growing concerns about China's economy and uncertainties with the country's healthcare reform, the pharmaceutical industry has remained generally positive about the future outlook of the Chinese healthcare market.

In the face of policy turbulences, pricing pressures and a host of other challenges, the pharmaceutical industry in China had shown unusual resilience last year and delivered

steady revenue growth but at lower margins. However, repeated price cuts and cost containment measures have hurt the pharma industry bottom line in 2011.

Large pharma companies, represented by state-controlled companies and MNCs, continued to reposition and expand through M&As, diversification drives, alliances and partnerships, and capacity building for both manufacturing and R&D in 2011.

Although the healthcare reform is relatively more successful in expanding its enrollment to over 95% of the Chinese population, it has made little progress on the part of public hospital reform, the core of healthcare reform, other than some superficial issues.

What sets this event apart from those organized by conference companies?

- It is an event organized by veteran executives for executives
- Hard-to find/exclusive industry and market information are presented and distributed at the event
- Only industry experts with real world experience are invited to present
- Cost effectiveness our goal for this event is not profit but to bring value-added services to our subscribers and potential customers.

The deadlock with reform of the Chinese healthcare financing mechanism and public hospitals is also blocking progresses in many other reform areas. Over-emphasis on price bidding by local governments has become a critical issue for provincial-level drug purchase tenders, especially those for essential drugs, and the aftermath is alarming with drug quality freefalling and shortage of low-cost medicines surging.

Drug pricing reform is also stuck, and under mounting public pressure, the NDRC had to initiate more price cuts, as disputes among stakeholders and government agencies continue to prevent it from coming up with a well-defined drug pricing reform framework.

Despite wide-ranging problems, the Chinese government did manage to raise its healthcare funding for both BMI programs. As a result, China's healthcare expenditure composition is undergoing major changes with falling share of personal out-of-pocket expenditures and rising shares of government expenditures and socialized expenditures.

A new Chinese government will fall into place after the 18th CPC Congress and Vice Premier Li Keqiang, who has been in charge of healthcare reform, is presumed to become the new Premier, so the Chinese healthcare reform is expected to stay on course.

The Pharma China Annual Forum 2012 is an English language annual pharma industry event oriented for foreign drug companies in China. The event's emphasis is on healthcare policies, drug regulations, market access issues as well as potential impacts of upcoming changes on the Chinese pharma industry. In addition, various trends in M&A and industry consolidation, R&D and licensing, dynamics of the Chinese healthcare landscape, as well as future market outlook will be explored and discussed.

At least five leading experts will share their knowledge, insights and expertise followed by an interactive panel discussion with speakers and other experts.

AGENDA

8:30-9:00	Simple registration, networking and refreshments		
9:00-9:05	Stanley Lau, COO, EddingPharm/Former GM, Baxter China		
	Opening remarks/welcome by chairman		
	James Shen, Publisher and Chief Editor, Pharma China		
	Review of recent trends and developments in the Chinese pharma industry		
9:05-10:30	- Market overview - 2011 and early 2012		
	- Latest trends of the pharmaceutical industry and market		
	- Latest developments in drug regulation and healthcare reform		
10:30-10:45	5 Break, refreshments and networking		
	Andy A. Liu, President, Asia Pacific and China, IMS Health		
	State of the pharmaceutical market: today and beyond		
10:45-11:30	- The pharmaceutical market view: Global vs. Asia Pacific vs. China		
10.45 11.50	- Current and future growth projections		
	- Key Market Trends in China		
	- Key Challenges and Opportunities in China		
11:30-12:30	Joseph Cho, Managing Director, RDPAC/Chairman, Astellas Pharma China		
	Contemporary market access issues and challenges for MNCs in China		
12:30 - 13:30	Networking lunch		
	Dr. Songjun Luo, Principal, ZS Associates Shanghai		
	MNC strategies and opportunities under changing dynamics of China		
13:30-14:15	healthcare		
	- Issues, challenges and trends		
	- Strategies, business models and corporate structures		
14:15-15:00	Simon Li, General Manager, Kantar Health China		
	Diabetes in China: market characters, trends and implications		
15:00-15:15	Break, refreshments and networking		
	Tony Zhang, Chief Consultant and Managing Partner, BizPro International Asia		
15:15 - 15:45	Structuring an effective sales and marketing organization to meet china's		
	healthcare reform challenges		
15:45 - 16:15	Richard Bird, IP Counsel, Freshfields Bruckhaus Deringer		
	Making co-marketing and co-promotion deals work in China		
16:15 - 16:45	Mai TRAN, Executive VP Asia, Health & Wellness, Ruder Finn Public Relations		
20,25 20,45	Social media strategies and opportunities for pharma companies in China		
16:45 - 17:15	Stanley Lau, COO, EddingPharm (Moderator)		
	Panel discussions with speakers		
After 17:15	Voluntary after-event Q&As, discussions and networking		

















REGISTRATION FORM

By email: <u>dxue@pharmaguys.com</u> or <u>jwanq.wicon@gmail.com</u>

+86 10 5885 7333 ext 0260 or +86 10 84476110

Please return this form:

By fax:

	•				
Ιv	vish to re	egister for:			
	Pharma China Annual Forum 2012				
	Date:	9:00 AM - 5:15 PM, March 30), 2012		
	Price:	☐ CNY 4,200 for Pharma Chin	a subscribers and RDPAC members		
		☐ CNY 5,500 for others			
	Place:	Rendezvous Merry Hotel Shan	ghai (美丽园龙都大酒店), China		
Re	gistratio	on Details:			
	Name: .	ne: Title			
	Compar				
	Address	5:			
	Telephone: Fax:				
	Email: .				
	Authori	zed signature:	Date		
Pa	yment &	Invoicing:			
	开户行 (Bank):交通银行北京分行东直门支行 账号: 110060439018002037015				
	帐户名 (Account Holder):北京集才医药技术开发有限公司(人民币帐户 — CNY Only)				
		d the official receipt to be sent via courier, in Chinese.	please type or print the official title of the company, mailing address		
	发票抬头:	·	快递地址及收件人:		
	If you a	pay by credit card or contact us for other options.			
	Please charge: ☐ Visa ☐ Mastercard ☐ Amex ☐ Discover for US\$				
	Card # _		Cardholder name		
	Cardhold	der Signature	Expiration Date		
	Card Code (the last 3 or 4 digit number at the back of card on signature line)				

Cancellation Polices:

Return of this form by email or fax is considered to be registered officially and liable to the following cancellation policy:

- More than 4 weeks, 100% of the fee is refunded
- 2-4 weeks, 75% of the fee is refunded

Cardholder's full billing address

- Less than 2 weeks, replacements or program transfer only
- We will confirm the event opening two weeks in advance of original schedule and reserve the right to cancel or postpone anytime should there be insufficient participants